Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology

Reuters

2025/09/23

<a href="https://laohu8.com/S/APDN">Applied DNA Sciences Inc</a>. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology

Applied DNA Sciences, Inc. (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR Summit in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2569902287"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569902287\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569902287?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569902287","market":"nz","top_or_hot":-1,"title":"Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APPDW\">Applied DNA Sciences, Inc.</a> (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR <a href=\"https://laohu8.com/S/SMMT\">Summit</a> in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AMAT\">Applied</a> DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-23 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/APDN\">Applied DNA Sciences Inc</a>. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APPDW\">Applied DNA Sciences, Inc.</a> (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR <a href=\"https://laohu8.com/S/SMMT\">Summit</a> in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AMAT\">Applied</a> DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APDN","symbol_name":"Applied DNA Sciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL2nGmhB:1","article_id":"2569902287","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569902287","pubTimestamp":1758630614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA Technology. Applied DNA Sciences, Inc. , a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia  and will be presented at the 10th Annual CAR-TCR Summit in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Scie","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APDN":"Applied DNA Sciences","BK4583":"猴痘概念","BK4121":"生命科学工具和服务"},"translate_title":"Applied DNA Sciences Inc.宣布启动使用合成LineaDNA的CD123特异性CAR-T细胞的I期临床试验™技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APDN":0.9},"content_text":"Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology\n    \n\nApplied DNA Sciences, Inc. (NASDAQ:APDN), a biotechnology company specializing in nucleic acid production solutions for the biopharmaceutical and diagnostics sectors, has announced the initiation of a Phase I clinical trial. This trial focuses on CD123-specific CAR-T cells produced using the synthetic LineaDNA™-based piggyBac transposon system. The study is aimed at patients with acute myeloid leukemia (AML) and will be presented at the 10th Annual CAR-TCR Summit in Boston. The presentation is scheduled for September 23, 2025, at 6:30 p.m. Eastern time.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied DNA Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1077175) on September 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}